Mofezolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RVJ0BV3H3Y, chemically known as 3,4-bis(p-methoxyphenyl)-5-isoxazoleacetic acid but generally known as mofezolac, which bears US NIH Compound Identifier 4237. European Medicines Agency schedules Mofezolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09035MIG. The term MOFEZOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). MOFEZOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mofezolac under HS 29349990 and SITC 51579. As of Q4 2014, MOFEZOLAC remains the US FDA Preferred Term for this commodity. Mofezolac bears US NLM identifiers UMLS ID C0043597 and NCI Concept Code C66176. SMILES: O1NC(C(C1CC(=O)O)C1CCC(OC)CC1)C1CCC(OC)CC1.